Psychedelic Psychiatry’s Brave New World | Zendy

David Nutt | Zendy; David Erritzøe | Zendy; Robin CarhartHarris | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Psychedelic Psychiatry’s Brave New World

Author(s) -

David Nutt,

David Erritzøe,

Robin CarhartHarris

Publication year - 2020

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2020.03.020

Subject(s) - psilocybin , context (archaeology) , addiction , hallucinogen , psychiatry , depression (economics) , neuroscience , psychology , biology , paleontology , macroeconomics , economics

After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research